Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Tuberculosis
Would you consider adding azithromycin to standard antituberculosis treatment to reduce inflammation and tissue damage in patients with pulmonary tuberculosis?
Dekkers BG, et al., PMID 39932906
Related Questions
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
What are your top takeaways from ID Week 2024?
What is your approach to a positive PPD or IGRA in a patient with well-controlled HIV without significant TB risk factors?
How would you approach treatment of latent TB for patients who cannot tolerate rifamycins or isoniazid due to allergy, intolerance, or drug-drug interactions?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
What is your preferred method for latent tuberculosis screening prior to outpatient hemodialysis initiation for a patient with new dialysis requirements?
Do you use oral beta-lactams to treat osteomyelitis?
How would you manage concurrent immunotherapy-related colitis and C. difficile infection?
Do you recommend procalcitonin to help convince other providers to stop antibiotics in patients with pneumonia in whom a non-infectious diagnosis is strongly suspected?
